

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 October 2000 (19.10.2000)

PCT

(10) International Publication Number
WO 00/61174 A3

- (51) International Patent Classification⁷: A61K 38/21, 47/48, A61P 35/00
- (21) International Application Number: PCT/US00/09127
- (22) International Filing Date: 6 April 2000 (06.04.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/288,359 8 April 1999 (08.04.1999) US
- (71) Applicant: SCHERING CORPORATION [US/US];
2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).
- (72) Inventors: ROSE, Esther, Helen; 755 Belvidere Avenue, Westfield, NJ 07090 (US). RYBAK, Mary, Ellen; 5 Chesterfield Drive, Warren, NJ 07059 (US).
- (74) Agents: WYATT, Donald, W. et al.; Schering-Plough Corporation, Patent Dept., K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— With international search report.
- (88) Date of publication of the international search report:
25 January 2001
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: USE OF PEGYLATED INTERFERON ALPHA FOR RENAL CELL CARCINOMA TREATMENT

(57) Abstract: Methods for treating treatment-naïve as well as treatment-experienced patients having RCC to achieve at least a partial tumor response involving administering a therapeutically effective amount of pegylated interferon-alfa, e.g., pegylated interferon alfa-2b as monotherapy or in association with a therapeutically effective amount of IL-2 are disclosed.

WO 00/61174 A3

INTERNATIONAL SEARCH REPORT

Intern 1al Application No

PCT/US 00/09127

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>ATZPODIEN JENS ET AL: "Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer." EUROPEAN JOURNAL OF CANCER, vol. 29A, no. SUPPL. 5, 1993, pages S6-S8, XP000953180 ISSN: 0959-8049 the whole document</p> <p>---</p>	14, 20
Y	<p>ATZPODIEN JENS ET AL: "Multiinstitutional Home-Therapy Trial of Recombinant Human Interleukin-2 and Interferon Alfa-2 in Progressive Metastatic Renal Cell Carcinoma." JOURNAL OF CLINICAL ONCOLOGY, vol. 13, no. 2, 1995, pages 497-501, XP000953198 ISSN: 0732-183X cited in the application the whole document</p> <p>---</p>	20
Y	<p>GEBROSKY NORMAN P ET AL: "Treatment of renal cell carcinoma with 5-fluorouracil and alfa-interferon." UROLOGY, vol. 50, no. 6, December 1997 (1997-12), pages 863-868, XP000953183 ISSN: 0090-4295 the whole document</p> <p>---</p>	14
Y	<p>WALTHER PHILIP J ET AL: "Treatment of metastatic renal cell carcinoma (RCC) with continuous infusion 5-fluorouracil and interferon alpha-2A in the home setting: A phase I-II trial." JOURNAL OF UROLOGY, vol. 155, no. 5 SUPPL., 1996, page 388A XP000953188 ISSN: 0022-5347 the whole document</p> <p>---</p>	14
A	<p>TALPAZ M ET AL: "Phase I study of polyethylene glycol (PEG) interferon alpha-2B (Intron-A) in CML patients." BLOOD, vol. 92, no. 10 SUPPL. 1 PART 1-2, 15 November 1998 (1998-11-15), page 251A XP000953118 ISSN: 0006-4971 the whole document</p> <p>---</p>	1-10, 12, 13, 15-19

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/09127

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	TALPAZ M ET AL: "Phase I study of pegylated-interferon alpha-2a (PEGASYSTM) in patients with chronic myelogenous leukemia (CML)." BLOOD, vol. 94, no. 10 SUPPL. 1 PART 1, 15 November 1999 (1999-11-15), page 530a XP000953172 ISSN: 0006-4971 the whole document ----	11
P,X	BUKOWSKI RONAL ET AL: "Phase I Study of Polyethylene Glycol (PEG) Interferon Alpha -2B (PEG INTRON) in Patients with Solid Tumors (Meeting abstract)." PROC ANNU MEET AM SOC CLIN ONCOL, vol. 18, May 1999 (1999-05), page A1719 XP000953163 the whole document ----	1-10,12, 13,15-19
P,X	WO 99 48535 A (SCHERING CORP ;KLINE DOUGLAS F (US)) 30 September 1999 (1999-09-30) the whole document especially page 12 line 19 - page 13 line 4 -----	1-20

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/09127

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9848840 A	05-11-1998	US 5908621 A	01-06-1999
		AU 7249098 A	24-11-1998
		BR 9809425 A	25-07-2000
		CN 1261806 T	02-08-2000
		EP 0975369 A	02-02-2000
		NO 995263 A	27-12-1999
		PL 336576 A	03-07-2000
		ZA 9803543 A	10-11-1998
US 5766582 A	16-06-1998	AT 194774 T	15-08-2000
		AU 708337 B	05-08-1999
		AU 3727995 A	02-05-1996
		BR 9509313 A	27-01-1998
		CA 2201749 A	18-04-1996
		CN 1160355 A	24-09-1997
		CZ 9701104 A	17-09-1997
		DE 69518084 D	24-08-2000
		EP 0777495 A	11-06-1997
		EP 0970703 A	12-01-2000
		FI 971486 A	10-04-1997
		HU 77287 A	30-03-1998
		JP 10506912 T	07-07-1998
		NO 971633 A	10-04-1997
		NZ 294464 A	29-03-1999
		PL 319603 A	18-08-1997
		SK 43997 A	08-10-1997
		WO 9611018 A	18-04-1996
		US 5935566 A	10-08-1999
WO 9948535 A	30-09-1999	AU 3181299 A	18-10-1999

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/09127

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/21 A61K47/48 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EP0-Internal, BIOSIS, WPI Data, PAJ, MEDLINE, CANCERLIT, CHEM ABS Data, EMBASE, SCISEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98 48840 A (SCHERING CORP) 5 November 1998 (1998-11-05) the whole document, especially page 8 lines 7-23	1-20
Y	US 5 766 582 A (YUEN PUI-HO C ET AL) 16 June 1998 (1998-06-16) cited in the application the whole document, especially column 6 lines 3-8	1-20



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

27 October 2000

Date of mailing of the international search report

08/11/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Stein, A



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 38/21, A61P 35/00	A2	(11) International Publication Number: WO 00/61174 (43) International Publication Date: 19 October 2000 (19.10.00)
(21) International Application Number: PCT/US00/09127 (22) International Filing Date: 6 April 2000 (06.04.00) (30) Priority Data: 09/288,359 8 April 1999 (08.04.99) US (71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US). (72) Inventors: ROSE, Esther, Helen; 755 Belvidere Avenue, Westfield, NJ 07090 (US). RYBAK, Mary, Ellen; 5 Chesterfield Drive, Warren, NJ 07059 (US). (74) Agents: WYATT, Donald, W. et al.; Schering-Plough Corporation, Patent Dept., K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).	(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: RENAL CELL CARCINOMA TREATMENT (57) Abstract Methods for treating treatment-naïve as well as treatment-experienced patients having RCC to achieve at least a partial tumor response involving administering a therapeutically effective amount of pegylated interferon-alfa, e.g., pegylated interferon alfa-2b as monotherapy or in association with a therapeutically effective amount of IL-2 are disclosed.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

RENAL CELL CARCINOMA TREATMENT

BACKGROUND OF THE INVENTION

This invention relates to an improved therapy for treating patients having renal cell carcinoma ("RCC") by administering a therapeutically effective dose of pegylated interferon-alfa for a time sufficient to achieve at least a partial tumor response.

Metastatic renal cell carcinomas are generally resistant to chemotherapy, either with single agents or in combination. Greater success has been seen with immunotherapy, particularly with the use of interleukin-2 ("IL-2"). Therapy with high dose intravenous IL-2 has resulted in objective tumor responses in approximately 14% of patients, some with long durability. The administration of high dose IL-2 is associated with capillary leak syndrome, which results in hypotension and reduced organ perfusion which can be severe and sometimes fatal. These toxicities have generally inhibited the use of IL-2 to a highly selected group of patients administered by physicians with significant experience in its administration. The use of lower-dose and subcutaneously (SC) administered regimens of IL-2 alone or in combination with other biologic agents, including interferon- α , has been explored in an effort to develop a more broadly applicable therapy for this disease. For example, Atzpodien, J., et al. disclosed in J. Clin Oncol., 1995, Volume 13, pages 497-501 that the combination treatment of subcutaneous ("SC") administration and lower dose regimens of interferon alfa-2b and SC interleukin-2 to patients with progressive metastatic RCC produced tumor response with lower toxicity. It must be noted that the response rates are low and that injections of interferon alfa-2b 5 million IU/m² three times a week ("TIW"), were required to achieve these results.

IU/m² three times a week ("TIW"), were required to achieve these results. In addition, interferon alfa-2b has many side effects that a substantial number of patients find unacceptable, and patient compliance with the TIW injections of interferon alfa-2b has become a problem. Accordingly, there is a need for an improved therapy for treating patients having RCC.

Summary of the Invention

The present invention provides a method of treating a patient having renal cell carcinoma which comprises administering to such a patient a therapeutically effective dose of pegylated interferon alfa for a time period sufficient to effect at least a partial tumor response.

The present invention also provides a method of treating a patient having metastatic renal cell carcinoma which comprises administering to said patient an effective amount of pegylated interferon-alfa once a week for a time period sufficient to effect at least a partial tumor response.

The present invention further provides a method of treating a patient having metastatic renal cell carcinoma which comprises administering to such a patient about 4.5 micrograms/kg to about 9.0 micrograms/kg of pegylated interferon alfa-2b once a week for a time period sufficient to effect at least a partial tumor response.

Detailed Description of the Invention

The present invention provides an improved method of treating patients with RCC-especially those with metastatic RCC. The improved method provides a safer and more efficacious and tolerable treatment for RCC by use of weekly injections of pegylated interferon alfa alone or in combination with immunotherapeutic agents such as IL-2 or fluorouracil

(5-FU"). The RCC patients include those newly diagnosed with this disease as well as those patients intolerant or resistant to interferon alfa. Treatment with pegylated interferon alfa in accordance with the present invention will continue for a minimum of six months, and preferably for at least twelve months unless there is clinical evidence of disease progression, unacceptable toxicity or the patient requests that the therapy be discontinued.

When the pegylated interferon-alfa administered is a pegylated interferon alfa-2b, the therapeutically effective amount of pegylated interferon alfa-2b administered is in the range of about 4.5 to about 9.0 micrograms per kilogram of pegylated interferon alfa-2b administered once a week (QW), preferably in the range of about 4.5 to about 6.5 micrograms per kilogram of pegylated interferon alfa-2b QW, more preferably in the range of about 5.5 to about 6.5 micrograms per kilogram of pegylated interferon alfa-2b QW, and most preferably in the range of about 6.0 micrograms per kilogram of pegylated interferon alfa-2b administered QW.

When the pegylated interferon-alfa administered is a pegylated interferon alfa-2a, the therapeutically effective amount of pegylated interferon alfa-2a administered is in the range of about 50 micrograms to about 500 micrograms once a week ("QW"), preferably about 200 micrograms to about 250 micrograms QW.

The term "pegylated interferon alfa" as used herein means polyethylene glycol modified conjugates of interferon alfa, preferably interferon alfa-2a and -2b. The preferred polyethylene-glycol-interferon alfa -2b conjugate is PEG₁₂₀₀₀-interferon alfa 2b. The phrases "12,000 molecular weight polyethylene glycol conjugated interferon alfa" and "PEG₁₂₀₀₀-IFN alfa" as used herein mean conjugates such as are prepared

according to the methods of International Application No. WO 95/13090 and containing urethane linkages between the interferon alfa-2a or -2b amino groups and polyethylene glycol having an average molecular weight of 12000.

The preferred PEG₁₂₀₀₀-interferon alfa-2b is prepared by attaching a PEG polymer to the epsilon amino group of a lysine residue in the IFN alfa-2b molecule. A single PEG₁₂₀₀₀ molecule is conjugated to free amino groups on an IFN alfa-2b molecule via a urethane linkage. This conjugate is characterized by the molecular weight of PEG₁₂₀₀₀ attached. The PEG₁₂₀₀₀-IFN alfa-2b conjugate is formulated as a lyophilized powder for injection. The objective of conjugation of IFN alfa with PEG is to improve the delivery of the protein by significantly prolonging its plasma half-life, and thereby provide protracted activity of IFN alfa.

The term " interferon-alfa " as used herein means the family of highly homologous species-specific proteins that inhibit viral replication and cellular proliferation and modulate immune response. Typical suitable interferon-alfas include, but are not limited to, recombinant interferon alfa-2b such as Intron-A interferon available from Schering Corporation, Kenilworth, N.J., recombinant interferon alfa-2a such as Roferon interferon available from Hoffmann-La Roche, Nutley, N.J., recombinant interferon alfa-2C such as Berofer alpha 2 interferon available from Boehringer Ingelheim Pharmaceutical, Inc., Ridgefield, CT., interferon alfa-n1, a purified blend of natural alfa interferons such as Sumiferon available from Sumitomo, Japan or as Wellferon interferon alfa-n1 (INS) available from the Glaxo-Wellcome Ltd., London, Great Britain, or a consensus alfa interferon such as those described in U.S. Patent Nos. 4,897,471 and 4,695,623 (especially Examples 7, 8 or 9 thereof) and the specific product available from Amgen, Inc., Newbury Park, CA, or interferon alfa-n3 a mixture of natural alfa interferons made by Interferon Sciences and

available from the Purdue Frederick Co., Norwalk, CT., under the Alferon Tradename. The use of interferon alfa-2a or alpha-2b is preferred. Since interferon alpha-2b, among all interferons, has the broadest approval throughout the world for treating chronic hepatitis C infection, it is most preferred. The manufacture of interferon alpha-2b is described in U.S. Patent No. 4,530,901.

Other interferon alfa conjugates can be prepared by coupling an interferon alfa to a water-soluble polymer. A non-limiting list of such polymers include other polyalkylene oxide homopolymers such as polypropylene glycols, polyoxyethylenated polyols, copolymers thereof and block copolymers thereof. As an alternative to polyalkylene oxide-based polymers, effectively non-antigenic materials such as dextran, polyvinylpyrrolidones, polyacrylamides, polyvinyl alcohols, carbohydrate-based polymers and the like can be used. Such interferon alfa-polymer conjugates are described in U.S. Patent No. 4,766,106, U.S. Patent No. 4,917,888, European Patent Application No. 0 236 987, European Patent Application Nos. 0 510 356 , 0 593 868 and 0 809 996 (pegylated interferon alfa-2a) and International Publication No. WO 95/13090.

Pharmaceutical composition of pegylated interferon alfa-suitable for parenteral administration may be formulated with a suitable buffer, e.g., Tris-HCl, acetate or phosphate such as dibasic sodium phosphate/monobasic sodium phosphate buffer, and pharmaceutically acceptable excipients (e.g., sucrose), carriers (e.g. human serum albumin), toxicity agents (e.g. NaCl), preservatives (e.g. thimerosal, cresol or benylalcohol), and surfactants(e.g. tween or polysorbates) in sterile water for injection. The pegylated interferon alfa-may be stored as lyophilized powders under a refrigeration at 2°-8°C. The reconstituted aqueous solutions are stable when stored between 2° and 8°C and used within 24 hours of reconstitution. See for example U.S. Patent Nos,

4,492,537; 5,762,923 and 5,766,582. The reconstituted aqueous solutions may also be stored in prefilled, multi-dose syringes such as those useful for delivery of drugs such as insulin. Typical suitable syringes include systems comprising a prefilled vial attached to a pen-type syringe such as the NOVOLET Novo Pen available from Novo Nordisk, as well as prefilled, pen-type syringes which allow easy self-injection by the user. Other syringe systems include a pen-type syringe comprising a glass cartridge containing a diluent and lyophilized pegylated interferon alfa powder in a separate compartment.

The term "tumor response" as used herein means a reduction or elimination of all measurable lesions.

The criteria for tumor response are based on the WHO Reporting Criteria [WHO Offset Publication, 48-World Health Organization, Geneva, Switzerland, (1979)]. Ideally, all uni- or bidimensionally measurable lesions should be measured at each assessment. When multiple lesions are present in any organ, such measurements may not be possible and, under such circumstances, up to 6 representative lesions should be selected, if available.

The term "complete response" ("CR") as used herein means a complete disappearance of all clinically detectable malignant disease, determined by 2 observations not less than 4 weeks apart. A preliminary assessment may be made with two measurements.

The term "partial response" ("PR") as used herein in reference to (a) bidimensionally measurable disease means decrease by at least about 50% of the sum of the products of the largest perpendicular diameters of all measurable lesions as determined by 2 observations not less than 4 weeks apart and (b) unidimensionally measurable disease means

decrease by at least about 50% in the sum of the largest diameters of all lesions as determined by 2 observations not less than 4 weeks apart. It is not necessary for all lesions to have regressed to qualify for partial response, but no lesion should have progressed and no new lesion should appear. Serial evidence of appreciable change documented by copies of radiographic studies must be obtained and must be available for subsequent review. The assessment should be objective.

The term "stable disease" ("SD") as used herein in reference to (a) bidimensionally measurable disease means less than about 50% decrease or less than about 25% increase in the sum of the products of the largest perpendicular diameters of all measurable lesions and (b) unidimensionally measurable disease, means less than about 50% decrease or less than about 25% increase in the sum of the diameters of all lesions. No new lesions should appear.

The term "progressive disease ("PD") as used herein means a greater than or equal to about a 25% increase in the size of at least one bidimensionally (product of the largest perpendicular diameters) or unidimensionally measurable lesion or appearance of a new lesion. The occurrence of pleural effusion or ascites is also considered as progressive disease if this is substantiated by positive cytology. Pathological fracture or collapse of bone are not necessarily evidence of disease progression.

Overall Subject Tumor Response

Determination of overall subject tumor response for uni- and bidimensionally measurable disease will be done according to the following table:

Overall Subject Tumor Response

<u>Response in Bidimensionally Measurable Disease</u>	<u>Response in Unidimensionally Measurable Disease</u>	<u>Overall Subject Tumor Response</u>
PD	Any	PD
Any	PD	PD
SD	SD or PR	SD
SD	CR	PR
PR	SD or PR or CR	PR
CR	SD or PR	PR
CR	CR	CR

PD: Progressive Disease.

CR: Complete Response.

PR: Partial Response.

SD: Stable Disease

Evaluation of Response in the Presence of Non-Measurable Disease

Non-measurable disease will not be used in the assessment of overall subject tumor response except in the following situations:

- a) **Overall complete response:** if non-measurable disease is present, it should disappear completely. Otherwise, the subject cannot be considered as an "overall complete responder".
- b) **Overall progression:** in case of a significant increase in the size of non-measurable disease or the appearance of a new lesion, the overall response will be progression.

The term "patients having renal cell carcinoma or "RCC" as used herein means any patient having RCC and includes treatment-naive patients as well as treatment-experienced patients as well as patients in the metastatic stage of RCC.

The term "treatment-naive patients" as used herein means patients with RCC-including newly-diagnosed RCC patients- who have never been treated with radiation therapy or any chemotherapy, e.g., fluorouracil ("5-FU") or hormonal therapy or immunotherapy, e.g. IL-2, as well as any interferon, including but not limited to interferon alfa, or pegylated interferon alfa.

The term "treatment-experienced patients" as used herein means those patients who have initiated some form of radiation therapy or hormonal therapy or chemotherapy including, but not limited to 5 FU, or immunotherapy including, but not limited to IL-2. Interleukin-2 is available under the PROLEUKIN[®] tradename from Chiron Corporation, Emeryville, CA 94608-3997. Fluorouracil or 5-FU is available as an injectable solution under the ADRUCIL[®] tradename from Pharmacia & Upjohn Co., Bridgewater, NJ 08807-12665

The effective amount of IL-2 when used is in the range of about 5 to about 20 million international units ("IU") per square meter of body surface area (m^2) three times per week ("TIW") administered subcutaneously. In a preferred embodiment of the method of the present invention, the dosage and dosage regimen for SC administration of IL-2 in combination with pegylated interferon alfa will be about 20 million IU/ m^2 TIW in the first week and every fourth week thereafter and about 5 million IU/ m^2 TIW in the subsequent weeks of treatment, e.g., weeks 2, 3, 5, 6, 7, 9, 10, 11 et seq.

The effective amount of 5-FU when used is in the range of about 12 mg/kg/day IV (not to exceed 800mg) for 5 days. If toxicity has not occurred, 6 mg/kg/day IV on days 7, 9, 11 and 13. For maintenance, if toxicity to the first course was minimal either repeat the course every 30 days or give 10 to 15 mg/kg (not to exceed 1 g) once a week, after

recovery from the initial toxicity is complete. These doses may be reduced by the clinician depending upon the severity of the disease and the patient's condition and reaction to pegylated interferon alfa. A constant infusion with an implantable pump may be more effective and fewer toxic than periodic bolus injections.

Pegylated interferon-alfa formulations are not effective when administered orally, so the preferred method of administering the pegylated interferon-alfa is parenterally, preferably by subcutaneous, IV, or IM, injection. Of course, other types of administration of both medicaments, as they become available are contemplated, such as by nasal spray, transdermally, by suppository, by sustained release dosage form, and by pulmonary inhalation. Any form of administration will work so long as the proper dosages are delivered without destroying the active ingredient.

The following Clinical Study Design may be used to treat RCC patients in accordance with the method of the present invention. Many modifications of this Clinical Study Design protocol will be obvious to the skilled clinician, and the following Study Design should not be interpreted as limiting the scope of the method of this invention which is defined by the claims listed hereinafter

Clinical Study Design

In a preferred embodiment of the treatment method of the present invention, subjects with metastatic RCC will receive pegylated interferon alfa 2b, i.e., PEG₁₂₀₀₀-interferon alfa 2b at doses of 6.0 micrograms per kilogram by subcutaneous injection once a week .

Duration of Study and Visit Schedule

The duration of this study is based upon achieving a therapeutic response, and will be determined for each subject individually.

Treatment with PEG Intron will continue for a minimum of 6 months unless there is evidence of disease progression, unacceptable toxicity, or the subject requests that therapy be discontinued. Tumor response will be assessed beginning at week 8 will be evaluated every 8 weeks thereafter during the first year of study treatment. Population pharmacokinetics will be conducted at various timepoints throughout the study. In addition, quality of life and overall survival data will be collected. Subjects who achieve a complete or partial tumor response by 6 months will continue treatment for another 6 months.

The following clinical protocol may be used to administer the RCC therapy of the present invention:

The study population will include male and female patients with metastatic RCC and will be included if they meet the following inclusion and exclusion criteria:

Subject Inclusion Criteria

A subject is eligible to participate in this study if he or she:

- a) has histologically documented metastatic renal cell carcinoma.
- b) has an ECOG Performance Status of 0 or 1.
- c) is ≥ 18 and ≤ 70 years of age.

- d) has a life expectancy of >8 weeks.
- e) has adequate end organ function (hepatic, renal, bone marrow, cardiac) as indicated by laboratory values below:
 - 1) Hematology:
 - Absolute neutrophil count (ANC) $\geq 3,000$ cells/ μ L.
 - Platelet count $\geq 100,000$ cells/ μ L.
 - Hemoglobin concentration ≥ 9 g/dL.
 - 2) Renal and hepatic function:
 - Serum creatinine ≤ 1.8 mg/dL or calculated creatinine clearance of ≥ 50 mL/minute.
 - Serum bilirubin ≤ 1.25 times the upper limit of normal (ULN), unless due to infiltration by disease.
 - AST/ALT (SGOT/SGPT) ≤ 1.25 times ULN, unless due to infiltration by disease.
 - Negative HBs Ag.
 - 3) Normal plasma calcium.
- f) has submitted a written voluntary informed consent before study entry, is willing to participate in this study and will complete all follow up assessments.

Subject Exclusion Criteria

A subject is not eligible to participate in this study if he or she:

- a) has received any prior non-surgical treatment for RCC, including chemotherapy, adjuvant chemotherapy, immunotherapy, radiation therapy or hormonal therapy.
- b) has evidence of CNS metastases.
- c) has a known hypersensitivity to interferon- α .
- d) has severe cardiovascular disease i.e., arrhythmias requiring chronic treatment or congestive heart failure (NYHA classification III or IV)
- e) has a history of a neuropsychiatric disorder requiring hospitalization.
- f) has a history of seizure disorder.
- g) has thyroid dysfunction not responsive to therapy.
- h) has uncontrolled diabetes mellitus.
- i) has a life-threatening second active malignancy.
- j) has an ongoing active infection requiring antibiotics.
- k) requires chronic treatment with systemic corticosteroids.
- l) has a history of seropositivity for HIV.
- m) is pregnant, lactating or of child-bearing potential and not practicing an effective means of contraception.
- n) has active hepatitis.
- o) is known to be actively abusing alcohol or drugs.
- p) has received any experimental therapy within 30 days of enrollment into this study. and
- q) has not recovered from the effects of any recent surgery.

Subject Discontinuation Criteria

It is the right and duty of the clinical investigator to interrupt the treatment of any subject whose health or well being may be threatened by continuation in this study.

A subject may be discontinued prior to completion of the study if he or she:

- a) has a clinically significant adverse event as determined by the Principal Investigator.
- b) requests to be withdrawn from the study.
- c) is unable to complete the study evaluations/visits because of unforeseen circumstances.
- d) develops other conditions for which, in the investigator's opinion, it is in the subject's best interest to be withdrawn from the study.
- e) develops severe depression or any other psychiatric disorder requiring hospitalization.
- f) experiences a serious allergic response to the study drug manifested by angioedema, bronchoconstriction or anaphylaxis.

Another Clinical Study Design

In another preferred embodiment of the treatment method of the present invention, subjects with metastatic RCC will receive pegylated interferon alfa 2b, i.e., PEG₁₂₀₀₀-interferon alfa 2b at doses of 6.0 micrograms per kilogram by subcutaneous injection once a week in combination with SC administration of IL-2 in accordance with the following regimen: 20 million IU of IL-2/M² TIW in week 1 and every fourth week thereafter and 5 million IU of IL-2/M² TIW in weeks 2, 3, 5, 6, 7, 9, 10, 11 et seq.

Analysis of Primary and Secondary Endpoints

The primary efficacy endpoint will be the tumor response at 6 months. The primary analysis will be the comparison of treatment groups with respect to the proportion of subjects with major tumor response at 6 months using the Cochran Mantel-Haenszel test adjusting for strata.

Odds ratio and 95% confidence intervals for the odds ratio will be summarized.

The secondary endpoints of the study will be relapse-free survival at 3, 6 and 12 months, and overall survival. Relapse-free survival and overall survival will be analyzed using the log-rank statistic. Kaplan-Meier estimates of the survival curves will be provided. Hazard ratio and 95% confidence interval for the hazard ratio will be obtained using Cox's proportional hazards model.

What is claimed is:

1. A method of treating a patient having renal cell carcinoma which comprises administering to such a patient a therapeutically effective dose of pegylated interferon alfa for a time period sufficient to effect at least a partial tumor response.
2. The method of claim 1 wherein the pegylated interferon is pegylated interferon alfa-2a or pegylated interferon alfa-2b.
3. The method of claim 2 wherein the patient is a treatment-naive patient.
4. The method of claim 3 wherein the treatment-naive patient is one having newly diagnosed renal cell carcinoma.
5. The method of claim 1 wherein the patient is treatment-experienced patient.
6. The method of claim 5 wherein the treatment experienced patient is intolerant to interferon alfa or resistant to interferon alfa.
7. The method of claim 1 wherein the time period is at least 3 months.
8. The method of claim 1 wherein the tumor response is a complete tumor response.
9. A method of treating a patient having metastatic renal cell carcinoma which comprises administering to said patient an effective amount of pegylated interferon-alfa once a week for a time period sufficient to effect at least a partial tumor response.

10. The method of claim 9 wherein the pegylated interferon alfa is pegylated interferon alfa-2b and the effective amount is in the range of about 4.5 micrograms/kg to about 9.0 micrograms/kg administered once a week.
11. The method of claim 9 wherein the pegylated interferon alfa is pegylated alfa-2a and the effective amount is in the range of about 200 microgram to 250 administered once a week.
12. The method of claim 9 wherein the time period is at least 3 months.
13. The method of claim 9 wherein the time period is at least 6 months.
14. The method of claim 9 which further comprises administering an effective amount of fluorouracil.
15. A method of treating a patient having metastatic renal cell carcinoma which comprises administering to such a patient about 4.5 micro-grams/kg to about 9.0 micrograms/kg of pegylated interferon alfa-2b once a week for a time period sufficient to effect at least a partial tumor response.
16. The method of claim 15 wherein the time period is at least 6 months.
17. The method of claim 15 wherein the time period is at least 12 months.
18. The method of claim 15 wherein about 4.5 to about 6.5 micrograms/kg of pegylated interferon alfa-2b is administered once a week.
19. The method of claim 15 wherein a complete tumor response is effected.

20. The method of claim 15 which further comprises administering an effective amount of IL-2.